Ketim Technologies Confirms Novelty of Biomarkers for Postpartum Depression Following International Type Search
Brisbane, Australia – June 19, 2025 – Ketim Technologies has achieved a major intellectual property milestone, with an International Type Search (ITS) confirming the novelty of its biomarker discoveries for diagnosing, monitoring, and treating postpartum depression (PPD) and other neurological disorders.
The ITS, conducted on the company’s two provisional patents, confirmed that the identified biomarkers are novel over all prior art, with one biomarker found to be 100% novel and inventive — representing a previously undiscovered finding in any scientific literature or patent record. This validation significantly strengthens Ketim Technologies’ IP position ahead of its planned PCT filing in January 2026.
In parallel, the company is preparing a third provisional patent based on computational and in silico modelling work that has identified a potential novel therapeutic target for PPD. The biomarker panel has demonstrated predictive accuracy ranging from 65–94% in preliminary analyses, depending on marker permutations, with the next phase focused on determining the optimal combination for sensitivity, specificity, and analytical validation.
“This result confirms that we are breaking truly new ground in maternal mental health diagnostics,” said Dr. Clarissa Yates, CEO and Founder of Ketim Technologies. “It brings us closer to delivering a predictive blood test for PPD during pregnancy — months before symptoms appear — and opens the door to new therapeutic possibilities.”
The announcement coincides with Dr. Yates’ participation in the Pathology Technology Australia TGA IVD Intermediate Course in Sydney, funded through the Industry Growth Program with AusBiotech and the Department of Industry, Science and Resources. This engagement provided direct interaction with TGA officials to inform the company’s upcoming pre-submission meeting and clinical trial planning at the Mater Hospital.
For media inquiries, please contact:
Dr. Clarissa Yates
CEO, Ketim Technologies
clarissa.yates@ketim.com.au
